Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
56
PGEN Quote, Financials, Valuation and Earnings
Last price:
$4.16
Seasonality move
:
13.43%
Day range:
$4.05 - $4.24
52-week range:
$0.69 - $5.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
196.22x
P/B ratio:
35.16x
Volume:
2.8M
Avg. volume:
5.2M
1-year change:
463.15%
Market cap:
$1.5B
Revenue:
$3.9M
EPS (TTM):
-$1.40
Analysts' Opinion
-
Consensus RatingPrecigen, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.50, Precigen, Inc. has an estimated upside of 104.33% from its current price of $4.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $4.16.
Fair Value
-
According to the consensus of 2 analysts, Precigen, Inc. has 104.33% upside to fair value with a price target of $8.50 per share.
PGEN vs. S&P 500
-
Over the past 5 trading days, Precigen, Inc. has underperformed the S&P 500 by -1.61% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Precigen, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Precigen, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Precigen, Inc. reported revenues of $2.9M.
Earnings Growth
-
Precigen, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Precigen, Inc. reported earnings per share of -$1.06.
Enterprise value:
1.4B
EV / Invested capital:
--
Price / LTM sales:
196.22x
EV / EBIT:
--
EV / Revenue:
229.67x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-19.16x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$640K
Return On Assets:
-195.32%
Net Income Margin (TTM):
-3912.92%
Return On Equity:
-711.28%
Return On Invested Capital:
-420.48%
Operating Margin:
-1180.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $6.8M | $4M | $6.3M | $953K | $2.9M | |
| Gross Profit | -$2.9M | -$4M | $640K | -$374K | $1.6M | |
| Operating Income | -$87.3M | -$95.4M | -$107.7M | -$21.3M | -$34.5M | |
| EBITDA | -$80.6M | -$89.9M | -$104.9M | -$20.6M | -$33.7M | |
| Diluted EPS | -$0.37 | -$0.55 | -$1.40 | -$0.09 | -$1.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $153.1M | $162.8M | $93M | $34.5M | $129.6M | |
| Total Assets | $376.9M | $259.2M | $190.7M | $83.5M | $171.3M | |
| Current Liabilities | $29M | $104.9M | $32.9M | $21.2M | $32.1M | |
| Total Liabilities | $245.7M | $116.7M | $43M | $28.1M | $129.4M | |
| Total Equity | $131.2M | $142.5M | $147.7M | $55.4M | $41.9M | |
| Total Debt | $193.3M | $90M | $6.2M | $4.8M | $97.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$66.6M | -$75.7M | -$72.6M | -$22.7M | -$29.1M | |
| Cash From Investing | -$5M | $57.9M | -$106.8M | $5.7M | -$63.4M | |
| Cash From Financing | -$9.7M | $32.2M | $169M | $32.1M | $93M | |
| Free Cash Flow | -$67.1M | -$84.3M | -$75.6M | -$23.6M | -$29.5M | |
PGEN
Sector
Market Cap
$1.5B
$28.2M
Price % of 52-Week High
79.62%
51.2%
Dividend Yield
0%
0%
Shareholder Yield
-8.33%
-1.54%
1-Year Price Total Return
463.15%
-18.1%
Beta (5-Year)
1.162
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.14
200-day SMA
Buy
Level
$2.63
Bollinger Bands (100)
Buy
Level
3.05 - 4.39
Chaikin Money Flow
Buy
Level
6.6M
20-day SMA
Buy
Level
$3.84
Relative Strength Index (RSI14)
Buy
Level
56.00
ADX Line
Buy
Level
27.72
Williams %R
Neutral
Level
-33.9286
50-day SMA
Buy
Level
$3.98
MACD (12, 26)
Buy
Level
1.14
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
41.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-18.7397)
Sell
CA Score
(Annual)
Level (-2.7627)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (5.5976)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Stock Forecast FAQ
In the current month, PGEN has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PGEN average analyst price target in the past 3 months is $8.50.
-
Where Will Precigen, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Precigen, Inc. share price will rise to $8.50 per share over the next 12 months.
-
What Do Analysts Say About Precigen, Inc.?
Analysts are divided on their view about Precigen, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Precigen, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Precigen, Inc.'s Price Target?
The price target for Precigen, Inc. over the next 1-year time period is forecast to be $8.50 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PGEN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Precigen, Inc. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of PGEN?
You can purchase shares of Precigen, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Precigen, Inc. shares.
-
What Is The Precigen, Inc. Share Price Today?
Precigen, Inc. was last trading at $4.16 per share. This represents the most recent stock quote for Precigen, Inc.. Yesterday, Precigen, Inc. closed at $4.16 per share.
-
How To Buy Precigen, Inc. Stock Online?
In order to purchase Precigen, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PGEN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PGEN
Sector
P/E ratio
--
23.92x
PEG ratio
-0.02x
-0.01x
P/B ratio
35.16x
1.83x
Price / LTM sales
196.22x
1.61x
Growth Metrics
PGEN
Sector
Revenue growth
206.61%
4.6%
Earnings growth
-1118.87%
10.88%
Revenue (5-year growth)
-46.64%
6.46%
Earnings forecast
-$0.02
-$0.21
Profitability
PGEN
Sector
Profitability FY 2024
-$3.4M
$3.5M
Return on invested capital
-420.48%
-31.84%
Return on assets
-195.32%
-27.96%
Return on equity
-711.28%
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
12
Balance Sheet
PGEN
Sector
Total cash
$121.1M
$26.3M
Short term investments
$68.4M
$25.7M
Total assets
$146.5M
$76.9M
Long term debt
$97.1M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
